Welcome to our dedicated page for Sharp Therapeutics news (Ticker: SHRXF), a resource for investors and traders seeking the latest updates and insights on Sharp Therapeutics stock.
Sharp Therapeutics Corp. (TSX-V: SHRX, OTCQB: SHRXF) is a preclinical-stage biotechnology company focused on small-molecule therapeutics for genetic diseases. Its news flow centers on research and development progress, pipeline updates, and capital markets milestones related to its publicly traded shares.
Recent announcements have highlighted Sharp’s investment in programs targeting Gaucher disease, Niemann-Pick disease type C, Progranulin-associated indications, and familial frontotemporal dementia. The company has also discussed its lead '901 program, described as a Phase 1 ready small-molecule candidate for Gaucher disease and GBA Parkinson's disease, and has presented preclinical data at industry conferences such as the World Orphan Drug Congress.
Investors following SHRXF news can expect updates on quarterly financial results, research spending trends, and the advancement of preclinical programs toward Phase I clinical trials, as described by the company. Additional news items include information on trading developments, such as the listing of Sharp’s common shares on the OTCQB market and related steps like applying for DTC eligibility to facilitate electronic settlement.
This news page aggregates company-issued releases and market-facing announcements related to Sharp Therapeutics’ pipeline, scientific presentations, and trading status. It provides a centralized view of how the company describes its progress in developing small-molecule, pill-based therapies for genetically defined diseases and how it communicates with shareholders through its dual listings in Canada and the United States.
Sharp Therapeutics (OTCQB: SHRXF) appointed Robin Ely, M.D., co-founder and Clinical Director of the National Gaucher Foundation, to its Advisory Board effective Jan 27, 2026. Dr. Ely brings patient‑advocacy experience, internationally recognized clinical research in Gaucher disease, and leadership in global diagnostic and treatment initiatives. Sharp said Dr. Ely will advise on its program ‘901 for Gaucher disease’ and on preparatory activities as the company plans to initiate clinical studies later in 2026.
Sharp Therapeutics (OTCQB: SHRXF; TSXV: SHRX) released condensed interim consolidated financial statements for the three and nine months ended September 30, 2025 and related MD&A.
The company reported it increased R&D spending by 34% versus the comparable quarter in 2024 to advance its Gaucher, Niemann Pick C and Progranulin programs and is targeting entry into Phase I clinical trials in 2026. Sharp describes itself as a pre-clinical small-molecule therapeutics developer using computationally optimized libraries and high-throughput screening.
Sharp Therapeutics (OTCQB: SHRXF) will present preclinical data for its lead, Phase 1–ready small‑molecule ‘901 program targeting Gaucher disease and GBA Parkinson's disease at the World Orphan Drug Congress 2025 in Amsterdam on Oct 27–29, 2025. The company will present on Oct 27 at 2:45 p.m. CET and will review its clinical targets and pipeline, including programs for Niemann‑Pick disease type C and familial frontotemporal dementia. Sharp describes ‘901 as an oral candidate designed to restore lysosomal enzyme function with potential to treat peripheral and CNS manifestations and notes plans to initiate clinical studies in the near term.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has announced its Q2 2025 financial results and its listing on the OTCQB market. The company reported an 85% increase in R&D spending compared to Q2 2024, primarily focused on their Gaucher and Progranulin programs.
The pre-clinical stage company, which develops small-molecule therapeutics for genetic diseases, has expanded its market presence through the OTCQB listing and has applied for DTC eligibility to enhance trading accessibility. Sharp is progressing toward Phase I clinical trials planned for 2026, utilizing its discovery platform that combines high-throughput screening technologies with computationally optimized compound libraries.